

# RESECTABILITY IN STAGE III NSCLC:

## CASE-BASED CONSIDERATIONS FOR CLINICAL DECISION-MAKING

### PROGRAM OBJECTIVES

- Describe updates to the AJCC staging guidelines for lung cancer
- Explore rationales for determining resectability in Stage III disease
- Review NCCN treatment guidelines for Stage III NSCLC
- Discuss the clinical decision-making process in an MDT setting

**JOIN US FOR A PRESENTATION ON UPDATES  
TO NSCLC STAGING GUIDELINES, FOLLOWED  
BY AN INTERACTIVE DISCUSSION ON  
BORDERLINE RESECTABLE STAGE III NSCLC  
USING REAL-WORLD PATIENT CASES**

**DATE:**  
Monday, October 7, 2019

**TIME:**  
6:00 PM Pacific

**LOCATION:**  
Forbes Mill Steakhouse  
206 North Santa Cruz Avenue  
Los Gatos, CA 95030

**SPEAKER NAME AND AFFILIATION:**  
ERIC VALLIERES, MD  
Swedish Cancer Institute at Swedish Medical Center  
Seattle, WA  
Surgical Director, Lung Cancer Program

**RSVP:**  
[whitney.dunn@astrazeneca.com](mailto:whitney.dunn@astrazeneca.com)

**CONTACT NUMBER:**  
(408) 421-9084

Topics will include multistation disease, incidental N2 disease, single station bulky disease, and invasive T4 disease with N1 nodal involvement

